Building on QbD Group's Landing in Europe MedTech whitepaper, this webinar explains why EU market entry requires a fundamentally different approach than you might expect. We'll explore where home-market regulatory logic breaks down in Europe — with a specific focus on clinical evidence expectations, Notified Body interactions, and lifecycle obligations.
FDA approval often creates a false sense of readiness
For many MedTech companies, FDA or NMPA approval feels like the hard part is done. But when it comes to entering Europe, it is often just the beginning. Non-EU manufacturers frequently underestimate how different the regulatory and clinical expectations are under MDR and IVDR — and that gap shows up fast: in Notified Body pushback, in missing clinical evidence, and in timelines and costs that spiral out of control.
This webinar cuts through the complexity. We'll show you why EU market entry demands a fundamentally different strategy and how bringing your regulatory and clinical planning together from day one is the only reliable way to stay in control of your European launch.